The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.
 
Kim Anna Reiss
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Carisma Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Tesaro (Inst)
 
Yuan Yuan
Consulting or Advisory Role - BCI Pharma; Diiachi; Eisai; Genentech; Guardant Health; Immunomedics; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Genentech
Research Funding - Genentech; Imugene; Merck; Novartis; Pfizer
Expert Testimony - Novartis
 
Naoto T. Ueno
Honoraria - Amgen; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Henry Stewart Talks; Kyowa Hakko Kirin; Novartis; Pfizer; Puma Biotechnology; Rakuten Medical; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Immunomedics; Kechow Pharma; OncoCyte; Phoenix Molecular Designs; Takeda
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; Daiichi Sankyo; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Preferred Medicine; Puma Biotechnology; Sysmex
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncorus (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Turning Point Therapeutics (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); WindMIL (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Saar Gill
Stock and Other Ownership Interests - Carisma Therapeutics; Interius Biotherapeutics
Honoraria - Magellan Health
Consulting or Advisory Role - Asher Biotherapeutics
Research Funding - Carisma Therapeutics (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patents for chimeric antigen receptor T cells for acute myeloid leukemia
 
Elizabeth Claire Dees
Consulting or Advisory Role - Novartis (I); Sanofi
Research Funding - Genentech/Roche; H3 Biomedicine; Merck; Meryx Pharmaceuticals; Novartis; Pfizer
 
Joseph Chao
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Coherus Biosciences; Daiichi Sankyo; Foundation Medicine; Geneos; Lilly; Macrogenics; Merck; Novartis; Ono Pharmaceutical; Roche; Silverback Therapeutics; Turning Point Therapeutics
Speakers' Bureau - Bristol Myers Squibb; Merck
Research Funding - Brooklyn Immunotherapeutics (Inst); Merck (Inst); Novonco Therapeutics (Inst)
Travel, Accommodations, Expenses - Amgen; Foundation Medicine; Macrogenics; Merck
Other Relationship - Yiviva
 
Mathew Angelos
No Relationships to Disclose
 
Olga Shestova
No Relationships to Disclose
 
Jonathan Stuart Serody
Stock and Other Ownership Interests - Incyte; Roche/Genentech
Consulting or Advisory Role - Pique
Research Funding - Carisma Therapeutics (Inst); GlaxoSmithKline (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - I have pending patents for the use of ILC2 for the treatment/prevention of acute GvHD of the lower GI tract. I also have a patent pending for the use of STING agonists with CAR T cells to treat solid tumors. (Inst)
 
Saul Priceman
Stock and Other Ownership Interests - Adicet Bio; Imugene
Consulting or Advisory Role - Adicet Bio; Bayer; Imugene; MustangBio
Research Funding - Carisma Therapeutics; Imugene
Patents, Royalties, Other Intellectual Property - CAR Therapeutic; Oncolytic Virus Therapeutic
 
Debora Barton
Employment - Advanced Accelerator Applications; Carisma Therapeutics; Iovance Biotherapeutics
Leadership - Arovella Therapeutics
Stock and Other Ownership Interests - Advanced Accelerator Applications; Arovella Therapeutics; Carisma Therapeutics; Iovance Biotherapeutics
 
Ramona F. Swaby
Employment - Carisma Therapeutics; Merck; Prelude Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics; Merck
Travel, Accommodations, Expenses - Merck
 
Amy Ronczka
Employment - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics; Cryoport; Horizon Pharma; Schrodinger
Consulting or Advisory Role - Apricity Health
Travel, Accommodations, Expenses - Carisma Therapeutics
 
Thomas Condamine
Employment - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
Travel, Accommodations, Expenses - Carisma Therapeutics
 
Daniel Cushing
Employment - Carisma Therapeutics
Leadership - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
 
Rehman Qureshi
Employment - Carisma Therapeutics
 
Madison Kremp
Employment - Carisma Therapeutics
 
Michael Klichinsky
Employment - Carisma Therapeutics
Leadership - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
Patents, Royalties, Other Intellectual Property - Carisma Therapeutics
Travel, Accommodations, Expenses - Carisma Therapeutics
 
Yara Abdou
Consulting or Advisory Role - Exact Sciences